DNA Detector May Help Predict Recurrence in Women With Metastatic Breast Cancer

Article

Researchers at Johns Hopkins Kimmel Cancer Center have been studying the ability of a novel panel of cell-free DNA methylation markers to predict survival in women with metastatic breast cancer.

A new experimental blood test may be able to help better guide clinicians who are managing women with metastatic breast cancer (MBC). Researchers at Johns Hopkins Kimmel Cancer Center have been studying the ability of a novel panel of cell-free DNA methylation markers to predict survival in women with MBC. They evaluated a quantitative multiplex assay (cMethDNA) and found it could be used to help predict survival outcomes in MBC and may have clinical usefulness in risk stratification and disease monitoring.

This study was published in the November 2016 issue of Journal of Clinical Oncology.  

“There’s a great need in cancer patients to be able to quickly and easily assess if a particular treatment is working in order to switch to another if it’s not, thus avoiding wasted time, potential side effects and cost,” said Kala Visvanathan, MD, MHS, who is a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health and a professor of oncology at the Johns Hopkins University School of Medicine in Baltimore.

Hypermethylation often silences genes that keep runaway cell growth in check. Its appearance in the DNA code of breast cancer-related genes shed into the blood may indicate that a patient’s cancer growth is increasing and the disease has worsened. The researchers tested in duplicate serum samples on 10 genes from 141 women with MBC at baseline, at week 4, and at first restaging (usually after 12 weeks).

They looked at progression-free survival (PFS) and overall survival (OS) and used statistical models to evaluate the distribution of cancer-linked DNA in the patients’ blood samples over the 7-year study to find the largest degree of differences between patients with low and high levels of evidence of hypermethylation in their DNA. 

Among 128 of the 141 patients, the scientists found that the median PFS of 71 patients identified with high levels of cancer DNA in their blood was 2.1 months, compared with 5.8 months for 57 patients with low levels. In 129 patients, median (OS) for 62 patients identified with high levels of cancer DNA in their blood was 12.3 months, compared with 21.7 for 67 patients with low levels. Median follow-up of the women in the study was 19.5 months (range 0.8–86.3 months).

The study showed that this test may be valuable very early on in the course of the disease. Dr. Visvanathan said the current study did not look at the test’s benefits with regard to specific anticancer therapies. Currently, the researchers are also looking at the test in women with earlier stage breast cancer.

 

 

 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content